INmune Bio Inc.
INMB
$2.17
$0.094.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.97% | -25.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -74.60% | 6.17% | |||
| Operating Income | 74.60% | -6.17% | |||
| Income Before Tax | 76.46% | -2.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 76.46% | -2.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 76.46% | -2.72% | |||
| EBIT | 74.60% | -6.17% | |||
| EBITDA | 75.52% | -6.31% | |||
| EPS Basic | 76.60% | -2.78% | |||
| Normalized Basic EPS | 76.55% | -2.75% | |||
| EPS Diluted | 76.60% | -2.78% | |||
| Normalized Diluted EPS | 76.55% | -2.75% | |||
| Average Basic Shares Outstanding | 0.50% | -0.08% | |||
| Average Diluted Shares Outstanding | 0.50% | -0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||